Itolizumab Causes Equillium’s Skyrocketing Stock

Mostly biotech companies make news during the COVID-19 crisis and even small success may cause a significant rise in the majority of stocks. Dexamethasone and remdesivir gave some effects on stock indexes too.

Already existing itolizumab significantly reduced mortality in patients hospitalized with COVID-19 in India. Equillium’s (NASDAQ: EQ) partner Biocon is testing itolizumab which is developed to treat severe autoimmune and inflammatory disorders. Its opponents such as dexamethasone, avifavir and remdesivir already showing positive effects on treating COVID-19 patients but the completely striking vaccine doesn’t exist and possible creation may occur in 2021.

Equillium (EQ) more than triples with the change from $3.19 to $15.40 by rising volume to over 58 million shares. After several successful clinical trials of itolizumab EQ might soar higher again.